ReachRxResearch
Home
Research
Sign Up
Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localized Peritoneal Metastasis
Back to Research Hub
  1. Home
  2. Research Hub
  3. Treatment Outcomes for Gastric Cancer Wi…

Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localized Peritoneal Metastasis

JAMA Surgery·October 7
SurgeryPractice changingGastric CancerPeritoneal MetastasisRetrospective Cohort StudyConversion SurgeryGastrectomySystemic ChemotherapyOlder Adult

Summary

View source

What was studied

This retrospective multicenter cohort study (48 Japanese institutions, 2016–2022) compared treatment strategies — upfront gastrectomy vs. upfront chemotherapy, and various multimodal sequences — in 1,181 gastric cancer patients with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a), with no other distant metastases. The primary outcome was overall survival (OS).

Key findings

The overall 5-year OS was 25.0% (median survival 24.3 months). Upfront gastrectomy showed better OS than upfront chemotherapy (5-year OS 27.6% vs. 19.0%; HR 0.80; P = .004), but chemotherapy followed by gastrectomy after conversion to P0CY0 yielded the best outcomes of any strategy (5-year OS 50.5%), compared to 31.4% for upfront gastrectomy plus postoperative chemotherapy; gastrectomy alone and chemotherapy alone had poor 5-year OS rates of 10.3% and 3.2%, respectively.

Study limitations

Retrospective design with inherent selection bias — patients who achieved conversion to P0CY0 likely had more chemotherapy-sensitive disease; treatment allocation was not randomized, so direct strategy comparisons are confounded by patient and tumor characteristics not fully adjusted for.

Clinical implications

For gastric cancer with CY1 and/or P1a, multimodal therapy is essential — neither surgery nor chemotherapy alone is adequate. When feasible, pursuing preoperative chemotherapy to achieve P0CY0 conversion before gastrectomy appears to offer the best survival, making development of more effective perioperative regimens a priority.

Caveats

  • Median age of 72 years and predominantly male cohort (61%) should be considered when applying findings to younger or female-predominant populations
  • Retrospective, non-randomized design means patients selected for conversion surgery likely represent a biologically favorable subset, which may substantially inflate the 50.5% 5-year OS figure for that subgroup
  • The study population is entirely from Japanese institutions, which may limit generalizability to non-Asian populations with differing gastric cancer biology, staging practices, and chemotherapy protocols

Related Questions

Explore related topics

What chemotherapy regimens are most effective for converting peritoneal metastasis gastric cancer to P0CY0 before surgery?Conversion surgery outcomes in gastric cancer with peritoneal metastasis: systematic reviews and meta-analysesPeritoneal lavage cytology positive gastric cancer management guidelines and survival outcomes

Publication Details

Year
2026
Journal
JAMA Surgery
Sample Size
n=1,181
Source
View article
Keep scrolling
More content below.
Up Next